Head to Head Comparison: DXC Technology (NYSE:DXC) versus Portage Biotech (NASDAQ:ALP)

Portage Biotech (NASDAQ:ALP – Get Free Report) and DXC Technology (NYSE:DXC – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Profitability

This table compares Portage Biotech and DXC Technology’s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Portage Biotech and DXC Technology, as reported by MarketBeat.

Portage Biotech presently has a consensus price target of $0.25, suggesting a potential upside of 152.02%. DXC Technology has a consensus price target of $12.21, suggesting a potential upside of 4.93%. Given Portage Biotech’s higher probable upside, equities analysts plainly believe Portage Biotech is more favorable than DXC Technology.

Risk & Volatility

Portage Biotech has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, DXC Technology has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares Portage Biotech and DXC Technology”s top-line revenue, earnings per share (EPS) and valuation.

DXC Technology has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than DXC Technology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 96.2% of DXC Technology shares are owned by institutional investors. 1.1% of DXC Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DXC Technology beats Portage Biotech on 11 of the 13 factors compared between the two stocks.

About Portage Biotech

(Get Free Report)

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

About DXC Technology

(Get Free Report)

DXC Technology Company, together with its subsidiaries, provides information technology services and solutions in the United States, the United Kingdom, rest of Europe, Australia, and internationally. It operates in two segments, Global Business Services (GBS) and Global Infrastructure Services (GIS). The GBS segment offers a portfolio of analytics services and extensive partner ecosystem that help its customers to gain insights, automate operations, and accelerate their transformation journeys; and software engineering, consulting, and data analytics solutions, which enable businesses to run and manage their mission-critical functions, transform their operations, and develop new ways of doing business. This segment also simplifies, modernize, and accelerate mission-critical applications that support business agility and growth through applications services; provides proprietary modular insurance software and platforms; and operates a wide spectrum of insurance business process services, as well as helps to operate and improve bank cards, payment and lending process and operations, and customer experiences. The GIS segment offers security services, such as IT security, operations and culture for migrating to the cloud, protecting data with a zero-trust strategy, and manage a security operation center; and cloud infrastructure and IT outsourcing services. This segment also delivers a consumer-like experience, centralize IT management, and support services, as well as improves the total cost of ownership; and orchestrates hybrid cloud and multicloud environments. The company markets and sells its products through direct sales force to commercial businesses and public sector enterprises. DXC Technology Company was founded in 1959 and is headquartered in Ashburn, Virginia.